{"id":"tedizolid-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Optic neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2105669","moleculeType":"Small molecule","molecularWeight":"450.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits the initiation of protein synthesis. This mechanism is bacteriostatic, halting bacterial growth and allowing the immune system to clear the infection. Tedizolid is a prodrug that is converted to its active form in vivo and has enhanced potency and pharmacokinetics compared to linezolid, its predecessor.","oneSentence":"Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:20.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Community-acquired bacterial pneumonia (CABP)"}]},"trialDetails":[{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT03217565","phase":"PHASE1","title":"A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-02-06","conditions":"Gram-Positive Infections","enrollment":47},{"nctId":"NCT02444234","phase":"PHASE4","title":"Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":11},{"nctId":"NCT02097043","phase":"PHASE1","title":"Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":31},{"nctId":"NCT02750761","phase":"PHASE1","title":"A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Gram-Positive Bacterial Infections","enrollment":32},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT02019420","phase":"PHASE3","title":"Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-01-06","conditions":"Pneumonia","enrollment":726},{"nctId":"NCT01967225","phase":"PHASE3","title":"Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-23","conditions":"Skin Diseases, Infectious","enrollment":125},{"nctId":"NCT01421511","phase":"PHASE3","title":"TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-09-15","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":666},{"nctId":"NCT02342418","phase":"PHASE4","title":"Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults","status":"COMPLETED","sponsor":"Amit.Pai","startDate":"2015-03","conditions":"Obesity","enrollment":19},{"nctId":"NCT00983255","phase":"PHASE1","title":"Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-09","conditions":"Bacterial Infections","enrollment":90},{"nctId":"NCT01452828","phase":"PHASE1","title":"A Pharmacokinetics and Safety Study in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-10","conditions":"Renal Impairment","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sivextro","TR-701 FA","MK-1986"],"phase":"marketed","status":"active","brandName":"Tedizolid IV","genericName":"Tedizolid IV","companyName":"University of Southern California","companyId":"university-of-southern-california","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}